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Abstract
Metabolic syndrome (MetS) is a cluster of risk factors for atherosclerosis, including 
abdominal obesity, hypertension, insulin resistance, dyslipidemia with high triglyc-
erides, and low high-density lipoprotein cholesterol. Affected patients have a sig-
nificantly increased risk of developing cardiovascular disorders (CVD), that are the 
leading cause of death in the Western countries. Several epidemiological studies have 
investigated the evolution of CVD hypothesizing the presence of a gender difference in 
the pathogenetic and progression determinants detectable in men and women. In this 
chapter, we will examine new gender-associated bioindicators of possible diagnostic 
or prognostic value in the MetS. Moreover, we will provide an overview on current 
knowledge on sex-associated cardiovascular determinants with the aim to improve 
CVD diagnostic and prognostic clinical courses and to develop new and gender-biased 
prevention strategies.
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1. Introduction
This chapter is aimed to detect gender-associated biomarkers in metabolic syndrome (MS), 
a clustering of several risk factors associated with significant cardiovascular morbidity and 
mortality. Cardiovascular diseases (CVD) are the first cause of death in the world according 
to the World Health Organization. Over 17 million people died from CVD in 2015 and the 
economic burden of CVD each year is estimated at 396 billion dollars in the US, with similar 
perspective in Europe, and is expected to rise above 1 trillion dollars in 2030 [5]. Several epi-
demiological studies, the Framingham in particular, have investigated into the evolution of 
CVD hypothesizing the presence of a gender difference in the pathogenetic and progression 
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determinants detectable in men and women [36]. Metabolic syndrome contributes consider-
ably to cardiovascular mortality, particularly among women [33].
Here, we will examine new gender-associated bioindicators of possible diagnostic or prog-
nostic value in the MS. Moreover, we will provide an overview on current knowledge on 
sex-associated cardiovascular determinants with the aim to improve CVD diagnostic and 
prognostic clinical courses and to develop new and gender-biased prevention strategies.
2. Metabolic syndrome
In 1977, Haller used the term “metabolic syndrome” (MS) to describe the association between 
hypertension, dyslipidemia, obesity, and disturbed glucose metabolism [29]. In particular, he 
demonstrated how the presence of multiple of these factors increased the risk of developing 
cardiovascular disease [29]. Some years later, Phillips suggested that the combination of risk 
factors not only predisposed to heart disease, but was also related with an increased risk for 
obesity. This cluster of risk factors included glucose intolerance, hyperinsulinemia, and a high 
level of triglycerides, glucose, cholesterol, and insulin [73]. MS is due to the increase in body 
mass index (BMI) as result of an increase in caloric intake, increase in obesity percentage, 
and increased sedentary life habits [96]. As said before, this clinical entity has a cluster of risk 
factors such as hypertension, central obesity, increased triglycerides, decreased high-density 
lipoprotein cholesterol (HDL-C), increased blood glucose, and insulin resistance [11, 44]. The 
prevalence of the MS worldwide is estimated to be between 10 and 84%, highlighting a certain 
correlation with developed countries, but it also depends on various factors such as socioeco-
nomic status, lifestyle, BMI, and region studied [38, 96]. Moreover, a higher rate was found in 
urban compared with rural populations [76, 114].
A study by Khosravi-Boroujeni and coworker showed that the prevalence of MS has changed 
from 2001 to 2013 [41]. They also mentioned that incidence of diabetes has also been increas-
ing over the years. Data from the International Diabetes Federation (IDF) suggested that 25% 
of worldwide adult population suffer from the syndrome with 5% in those exhibiting normal 
weight, 22% being overweight, and 60% being obese [52, 114]. This has been attributed to 
aging, life style changes, population growth, obesity, and decline in physical activity. Central 
obesity was labeled as a critical component of the MS. The prevalence of the hypertriglyceri-
demia also declined, due to use of the statins, healthy eating with cutting back on fat [41].
3. Biomarker
3.1. Definition and characteristics
To predict cardiovascular risk, numerous biomarkers have been developed. Some of them are 
used in medicine to facilitate diagnosis, assess risk, direct therapy, and determine efficacy of 
treatment. The FDA-NIH Biomarker Working Group in the Biomarkers, Endpoints, and other 
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Tools (BEST) Resource (https://www.ncbi.nlm.nih.gov/books/NBK326791/) define a biomarker 
as “a defined characteristic that is measured as an indicator of normal biological processes, 
pathogenic processes, or responses to an exposure or intervention.” A clinically useful biomarker 
must be able to meet one of the following criteria: (i) show specificity and sensitivity for a certain 
disease (diagnostic); (ii) have prognostic value; and (iii) correlate with disease activity. Some of 
them are simple traditional biomarkers based on lipid profile and risk factors [74, 81, 93].
In the INTERHEART study, 9 major risk factors could explain 90% of the population-
attributable risk in men and 94% in women of 52 countries. These factors are abdominal 
obesity, elevated lipids, hypertension, diabetes, smoking, psychosocial factors, consumption 
of fruits/vegetables, consumption of alcohol, and regular physical activity [110]. However, 
the importance of these factors varies significantly from one country to another and some 
of these factors act as predisposing and not causal factors, like obesity and diet [111]. The 
prevalence of risk factors can change in different directions around the world, often because 
of socioeconomic and political cues.
Hypertension, central obesity, increased triglycerides, decreased high-density lipoprotein 
cholesterol (HDL-C), increased blood glucose and insulin resistance are collectively defined as 
risk factors for cardiovascular disease triggered by metabolic syndrome [11, 44, 62] (Table 1). 
In the last few years, in addition to the clinical factors, new factors in the pathogenesis of MS 
have also been taken into consideration. These factors can be classified on the basis of their 
function (e.g., marker of exposition, markers of effects, etc.) or in their biochemical or biologic 
properties (e.g., proteins metabolites, hormones, cytokines, etc.) [92].
Ample evidence favors a key role for mitochondrial injury, oxidative stress, and apoptosis in 
MS [7]. Moreover, recent findings depicted an essential role for autophagy, a cellular process 
of degrading long-lived, injured proteins and organelles, in the pathogenesis of MS [65, 108, 
114]. Indeed, dysregulated autophagy is present in multiple metabolic anomalies including 
obesity, insulin resistance, diabetes mellitus, and dyslipidemia [42, 47, 61, 112, 113].
Recent studies implicated that inflammation, especially chronic low-grade inflammation, 
might play an even greater role in the development of MS [56]. One possible mechanism 
is that the growth of adipose tissue and infiltration of immune cells lead to the increase of 
Components International Diabetes Federation
Obesity-waist circumference (cm) ≥35 cm for women or ≥ 40 cm for men
Hypertension-blood pressure (mmHg) 130/85 mm Hg
Dyslipidemia-reduced HDL (mg/dL) <40 mg/dL in men or < 50 mg/dL in women
Dyslipidemia-elevated triglycerides (mg/dL) ≥150 mg/dL
Glucose-fasting blood glucose (mg/dL) ≥100 mg/dL
HDL: high-density lipoprotein.
Table 1. Current criteria for the diagnosis of the metabolic syndrome.
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proinflammatory adipokines such as tumor necrosis factor alpha (TNF-α), C-reactive protein 
(CRP), and interleukin-6 (IL-6) [37, 59, 104, 105], which cause increased insulin resistance 
from insulin-sensitive tissues by decreasing insulin signaling [34].
We will present the current state of knowledge for modifiable biomarkers that can be used to 
predict MS events in the general population.
3.2. Elevated systolic blood pressure
Elevated systolic blood pressure (SBP) is one of the leading risk factors for global mortality 
and for CVDs. In 2015, the prevalence of raised blood pressure was around 20% in females 
aged 18 and over 24% in males [100]. Studies have reported conflicting results on the associa-
tion between increments in SBP and CVDs with differences between sexes [2]. An analysis 
carried out in 2013 found that every 10 mm Hg increment in SBP was associated with a 15% 
increased risk of coronary heart disease and a 25% increased risk of stroke in both men and 
women, indicating a similar impact of hypertension on cardiovascular outcomes in both sexes 
[71]. In contrast, a recent study on US population indicates that women experienced a 10% 
greater risk in CVDs per 10 mm Hg increment in SBP than men [103].
3.3. Dyslipidemia
Higher total cholesterol (TC) is estimated to account for over 2.6 million deaths (4.5% of total) 
worldwide every year [100]. The prevalence of elevated TC is similar in men and women 
[100] and studies addressing the possible sex-/gender-specific effects of TC on CVD risk have 
reported inconsistent results [72]. The cholesterol associated with high-density lipoproteins 
(HDL-C) has long been considered a useful biomarker of CVD and MS risk. In population 
studies, HDL-C is inversely related to the risk of myocardial infarction and death [57]. Low 
HDL was initially suggested to be more predictive of coronary risk in women compared to 
men [82]; however, analyses indicated that the association between HDL cholesterol levels 
and fatal coronary heart disease did not vary significantly by sex [22]. The first systematic 
meta-analysis evaluating the impact of TC on CVD risk in women compared with men [72] 
found that for every 1-mmol/L increment in TC, the risk of coronary heart diseases increased 
by 20% in women and by 24% in men, indicating essentially a similar TC-related risk of coro-
nary heart diseases in both sexes.
3.4. Triglycerides
Plasma triglycerides (TG) are product in the intestine and in the liver. As elevated TG are 
often associated with reduced levels of the negative cardiovascular risk biomarker HDL-C, the 
causal role of elevated plasma TG in CVD has been debated over the last 50 years. Fortunately, 
different types of genetic and epidemiological evidence have recently strengthened the cau-
sality relationship between TG and CVD and promoted TG lowering as a fundamental factor 
for CVD prevention. The question is important considering the high prevalence of TG levels: 
47% of the US population at over 1.7 mmol/L based on the 2011 NHANES survey [10].
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Initially, it was thought that TG level was a stronger risk biomarker in women than in men. 
Some years later, in a meta-analysis of 29 Western prospective studies with 262,525 subjects, a 
significant association of TG with cardiovascular events was found, which was attenuated by 
adjusting for HDL-C but remained significant [81, 88].
3.5. Body fat, excess body weight, and obesity
Excess body weight is another major risk factor for CVDs and MS; moreover, excess body 
weight is currently one of the greatest public health issues worldwide [99]. According to the 
WHO, over 650 million adults were estimated to be obese worldwide in 2016 and prevalence 
has almost tripled since 1975 confirming that excess body weight has reached epidemic pro-
portions globally. The association between BMI and coronary heart diseases has been shown 
to be the same between men and women in several studies [23, 66, 78]. The increased BMI has 
the same deleterious effects on the risk of MS onset in women and men [11, 62]. However, 
there are numerous differences between men and women regarding body fat, excess body 
weight, and obesity that could be due to either direct activation by sex steroids or by sex 
steroid-independent mechanisms.
3.6. Dysglycemia
Dysglycemia is a global term referring to either impaired fasting glucose or impaired glu-
cose tolerance. However, the two conditions are physiologically distinct. Impaired fasting 
glucose results from inadequate basal insulin secretion or sensitivity in the liver, whereas 
impaired glucose tolerance is a consequence of insufficient insulin response or sensitivity to 
a carbohydrate load in not only the liver but also skeletal muscle. Impaired glucose tolerance 
is more common in women than in men (except at older ages), whereas impaired fasting 
glucose is more often seen in men than in women. The reasons for this pattern are unknown, 
but sex differences in muscle mass, visceral adiposity, altered susceptibility to free fatty 
acid-induced peripheral insulin resistance, and other factors may play a role [77]. Because 
impaired glucose tolerance is not included in most current MS definitions, it is possible that, 
compared with their men counterparts, dysglycemic women are underdiagnosed with the 
syndrome [77].
3.7. High-sensitivity C-reactive protein
High-sensitivity C-reactive protein (hs-CRP) is a sensitive marker of inflammation. Some find-
ings have indicated that there is an association between CRP, development of atherosclerotic 
disease [83, 84], and components of the metabolic syndrome [25, 49]. Indeed, many studies 
have shown a direct association between high concentrations of CRP and insulin resistance or 
components of MS [17, 27, 39, 53, 87].
While elevated TGs do not exert an inflammatory stimulus per se, endothelial damage may 
occur, also because of the occurrence of intravascular TGs hydrolysis via the activity of lipo-
protein lipase either at the endothelial surface or within the arterial intima. This process leads 
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to a release of free fatty acids and monoacylglycerols which generate local inflammation and 
high levels of CRP [69, 86].
3.8. Mitochondria functions and its role in MS
Mitochondrial dysfunction is an early pathophysiological event in the development of insulin 
resistance and obesity [15]. The origin of mitochondrial dysfunction may relate to a variety 
of processes ranging from inflammation to epigenetic inheritance [48, 94]. Mitochondria are 
crucial, multifunctional organelles, which actively regulate cellular homeostasis. The main 
function of mitochondria is the energy production as adenosine triphosphate (ATP) via citric 
cycle (tricarboxylic acid cycle and Krebs cycle). Other cell functions include ionic homeo-
stasis, production and regulation of reactive oxygen species (ROS), lipid and carbohydrate 
utilization, pH regulation, steroid hormone synthesis, calcium homeostasis, thermogenesis, 
and cell death [70, 85, 98]. An intricate homeostatic system regulates and maintains optimal 
mitochondrial function in healthy cells, the failure of which is seen in obesity, asthma, and 
metabolic syndrome [6].
Mitochondria are known to adapt physically to nutrient availability [26, 79]. The study’s 
Durigon and coworker demonstrates that changes in nutrient availability and utilization 
remodel the nucleoprotein complexes in mitochondria and thereby indicates how nutrients 
can modulate gene expression and energy production in the organelle. It is clear that genetic 
defects in metabolic factors linked to mitochondrial nucleoprotein complexes, or their regu-
lators, can produce a pseudostarvation state, owing to an inability to utilize an available 
nutrient [21].
Several cardiovascular risk factors such as type 2 diabetes mellitus, hypertension, atrial fibril-
lation, peripheral artery disease, obesity, MS, dyslipidemia, habit of smoking, and pollution 
are associated with an increased production of ROS [75].
The most common cause of obesity, caloric excess, and high fat consumption, leads to nutri-
tional overload, excess electron flux, increased oxidative stress, accumulation of partially 
oxidized substrates, and, eventually, damage [45, 102]. As mentioned above, mitochondria 
are the primary intracellular site of oxygen consumption and the major source of reactive oxy-
gen species (ROS), most of them originating from the mitochondrial respiratory chain. These 
highly reactive molecules, radicals, and nonradicals have the ability to capture electrons from 
molecules they come in contact with, including proteins and nucleic acids, leading in conse-
quence to cell damage. A fine equilibrium between ROS production and ROS removal deter-
mines the physiological versus pathological function of ROS. In fact, an excessive amount of 
ROS induces oxidative stress and promotes cell death under hypoxic conditions. Conversely, 
at physiological levels, ROS function as “redox messengers” in intracellular signaling [18, 98]. 
ROS can be removed by antioxidant enzymes such as superoxide dismutase, catalase, and glu-
tathione peroxidase [18]. An efficient antioxidant system is also necessary to cope with reactive 
nitric species (RNS) generated by the reaction between O2− and nitric oxide (NO) [4]. Similar to ROS, excessive accumulation of RNS leads to irreversible damage to biomolecules [1].
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The mitochondrial dysfunction leads to activation of stress pathways that reduce cellular sen-
sitivity to insulin, limiting nutrient influx, and preventing further damage. Chronically, this 
manifests as reduced mitochondrial metabolism, insulin resistance in organs, such as liver 
and skeletal muscle, with consequent hyperinsulinemia and diversion of nutrients to stor-
age as adipose tissue [63]. In addition, mitochondrial dysfunction, with rising intracellular 
oxygen and oxidative stress, interferes with NO synthesis and leads to oxonitrative stress 
in epithelial and vascular endothelial cells. This pattern underlies the metabolic syndrome 
with obesity, diabetes, dyslipidemia, and hypertension as the phenotypic components. MS 
is thought to be related to inflammatory processes and oxidative stress that are linked to 
underlying adipocyte cellular dysfunction [3, 20].
3.9. Autophagy in MS
Autophagy (or self-eating) is a conserved process aimed at maintaining of cellular and tis-
sue homeostasis under normal as well as stress conditions, including nutrient starvation, 
changes in metabolism, energy and oxygen status. Autophagy is a degradation mechanism 
for nonessential or damaged cytoplasmic components, including damaged organelles, toxic 
protein aggregates, and intracellular pathogens [64]. It is an evolutionarily conserved process, 
in which cells engulf a portion of the cytoplasm and damaged organelles (such as mitochon-
dria, peroxisomes, and endoplasmic reticulum) into double-membraned vesicles which later 
fuse with lysosomes for the degradation of enclosed materials [14, 32, 50]. Degradation by-
products, such as amino acids, can then be re-used for the building of new macromolecules or 
for meeting metabolic demands [43, 109]. Autophagy serves as an indispensable process for 
cellular homeostasis involved in immunity, inflammation, and metabolism [16]. Either exces-
sive or defective autophagy may be associated with human metabolic diseases [91], indicating 
the unique role of autophagy in the regulation of metabolic homeostasis [114]. Besides the 
main function of energy production, mitochondria are also able to turn on and tune autoph-
agy by ROS production and oxidation of mitochondrial lipids. Excessive accumulation of ROS 
leads to impairment of mitochondria structure and function, which in turn triggers a selective 
process of mitochondria self-removal called mitophagy. As already mentioned, mitophagy 
is an autophagic response that allows elimination of defective mitochondria and accelerates 
the mitochondrial turnover, thus preserving the pool of healthy organelles [80]. It has been 
proposed that upon nutrient deprivation, mitochondria protect themselves from degrada-
tion by promoting fusion and inhibiting fission events. It is only after long-term starvation 
that mitochondria undergo fragmentation and are eventually removed by mitophagy [79]. A 
reciprocal regulatory mechanism exists between autophagy and key metabolic elements such 
as glucose and lipids [54, 55, 80]. For example, lipotoxicity in metabolic anomalies impairs 
lysosomal function and autophagy, further exacerbating lipid accumulation and ultimately 
cell injury [95]. Autophagy plays a pivotal role in the maintenance of the body’s metabolism. 
Clinical and experimental evidences have depicted a link between autophagy and metabolic 
risk factors such as obesity, dyslipidemia, alcoholism, insulin resistance, hypertension, diabe-
tes mellitus, sepsis, and inflammation [16, 51, 58, 90, 101, 114]. The bioengineered autophagy 
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models also show a key role of autophagy in systemic metabolic regulation. Specifically, 
they highlight how not only changes in autophagy affect metabolic homeostasis but also the 
metabolic stress affects the state of autophagy. Indeed, autophagy is suppressed in genetic or 
diet-induced models of obesity in various tissues, including liver, skeletal muscle, and cardiac 
muscle [12, 13, 31, 35, 54, 55, 106, 107]. Recent data show that elevated circulating insulin, an 
autophagy-inhibitory hormone, is believed to be responsible for changes in autophagy genes 
[89]. A more in-depth understanding of the role of autophagy in metabolic diseases should 
yield potential therapeutic strategies for better management of metabolic syndrome.
4. Metabolic syndrome and gender differences
Individuals with MS are four to five times more likely to develop diabetes and about twice as 
likely to develop CVDs than those without the syndrome [60, 77]. Recently, a meta-analysis 
of data from five cohorts with a total of 18,353 participants suggested that MS is associated 
with similar elevations in CVD risk in women and men [77]. It is unclear whether MS confers 
additional risk beyond its individual components. Comparative data from two U.S. National 
Health and Nutrition Surveys (NHANES III (1988–1994) and NHANES (1999-2006)) show 
a striking rise in prevalence of MS, with the relative increase larger in women (22.8%) than 
in men (11.2%) [68]. In NHANES III, the prevalence of specific risk factor clusters respon-
sible for the MS diagnosis differed between the sexes, at least in the cluster under age 65 
[46]. Abdominal obesity was a dominant feature in females with MS, whereas risk factor 
combinations were more heterogenous in their male counterparts. Sex affects not only the 
clinical expression but also the pathophysiology of MS. A recent review [77] demonstrates 
that sex differences in dysglycemia, body fat, adipocyte biology, and the hormonal control 
of body weight may have a role in cardiometabolic aftermath of women and men with the 
MS. Moreover, the estrogen decline, that occurs postmenopausally, may have also implica-
tions for cardiometabolic sequela in MS women [77].
The sex difference in the distribution of body fat is well known. Specifically, there is an adi-
pose tissue accrual in the upper body (trunk and abdomen) and lower body (hips and thighs) 
more prominent in men and women, respectively. Visceral adipose tissue in the abdomen is 
a stronger correlate than subcutaneous adipose tissue of metabolic disturbances and cardio-
vascular risk. The amount of visceral adipose tissue, as well as the ratio of visceral adipose 
tissue to total body fat, is lower in premenopausal women than in men. These findings imply 
that BMI and waist circumference, commonly used in epidemiologic settings, are less accurate 
indicators of visceral obesity in women and may thus underestimate the impact of visceral 
adipose tissue on cardiometabolic risk in this group [60].
Sex influences adipocyte size in certain anatomic locations. For example, in men, omental 
adipocytes (a type of intraperitoneal visceral adipose tissue) and abdominal subcutaneous 
adipocytes are approximately equal in diameter, and show only minimal size increases 
with increasing BMI. In contrast, in women, omental adipocytes are 20–30% smaller than 
abdominal subcutaneous adipocytes, and show larger size increases as BMI increases. Thus, 
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sex differences in adipocyte size may affect the cardiometabolic risk associated with MS in 
women and men [60].
Sex differences in hormonal control of body weight may also contribute to the clinical expres-
sion and sequelae of MS. The hormones insulin, leptin, and estrogen may interact to play a 
role in weight control via “adiposity signals” to the brain. In particular, insulin is secreted 
from pancreatic beta cells in response to rising glucose levels. Leptin, which has the effect 
of inhibiting food intake, suppressing insulin secretion, and increasing lipolysis, is released 
from adipose tissue in direct proportion to fat mass [19, 30]. Leptin expression is greater in 
subcutaneous than in visceral adipocytes, whereas insulin is a better marker of visceral than 
subcutaneous fat [19]. Given the aforementioned sex differences in visceral vs. subcutaneous 
fat, it seems likely that hormonal control of body weight varies in women and men. Sex differ-
ences in adipose tissue are not limited to white adipose depots, as females have more brown 
adipose tissue and an enhanced capacity to beige their adipose tissue [24].
The mass changes that occur in adipose tissue gene expression in response to diet-induced 
obesity are different between males and females, demonstrating significant differences in 
how obesity affects adipose tissue [28].
The estrogen family and its two respective receptors, ERα and ERβ, have been widely sug-
gested to be protective against obesity, type 2 diabetes, and cardiovascular disease [67]. 
Accumulating data also suggest that estrogen affects adipocyte biology, as well as glucose 
and lipid metabolism. Estrogens have significant effects on insulin and leptin sensitivity and 
on the body’s response to changes in glucose levels [19, 67]. At menopause, a time of fluctuat-
ing and ultimately falling estrogen levels, an increase in visceral adiposity occurs, along with 
atherogenic lipid changes characteristic of MS [60].
Estrogens can exert significant effects on one important cellular component as mitochon-
dria. Differences in mitochondrial number and function have been suggested to underlie the 
differences in life span between the sexes [97] and may also be responsible for some of the 
differences in response to the early life nutritional environment. Females have increased mito-
chondrial number in skeletal muscle, adipose tissue, and heart [8, 9, 40].
5. Conclusions
Progressive obesity, insulin resistance, abnormal cholesterol, or triglyceride levels that lead to 
metabolic syndrome are emerging problems. Many strategies have been recently proposed to 
minimize health-related consequences of metabolic syndrome. Sex seems to be the one element 
that plays a key role not only in the clinical expression but also in the pathophysiology of MS. The 
endogenous causes of the sex differences observed in many diseases are largely unknown, and 
the situation in CVD research is not much different. Much remains to be learned about mecha-
nisms for these sex differences. Gaining this knowledge would allow us to therapeutically target 
the relevant protective pathways. Sex differences in the clinical expression and physiology of 
metabolic syndrome may be important in refining predictions of cardiovascular risk.
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